Connect Biopharma announced that the independent Data Monitoring Committee has completed its interim analysis of the Phase 2 Seabreeze STAT trials for rademikibart, a potential best-in-class antibody for asthma and COPD. The committee recommended continuing enrollment as planned with no changes in sample size, confirming the treatment is well tolerated with no safety concerns. The company expects to report topline results from both studies in mid-2026 and plans to engage with the FDA to discuss Phase 3 development. This progress is significant as rademikibart targets the IL-4Rα receptor to treat inflammatory diseases with high unmet needs.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
B&M European Value Retail's first-quarter update has divided analysts, with Deutsche Bank upgrading the stock to 'hold' citing stabilizing profit margins and a sensible turnaround strategy by new CEO Tjeerd Jegen. Deutsche Bank raised its profit fore...
Telo Genomics announced positive interim results from a clinical study analyzing blood samples of multiple myeloma patients to predict relapse risk using 3D telomere analysis. The test showed strong predictive accuracy, potentially offering a less in...
Meta now notifies parents if their teen talks about suicide or self-harm with its AI chatbot and is developing a feature to contact emergency services if risk is detected. This move addresses concerns about AI chatbots handling crisis conversations, ...
NTG Clarity Networks announced new purchase orders and contract renewals totaling about CAD 16.6 million, reflecting strong demand for its software development and digital transformation services. This includes $2.3 million from a real estate client ...
